202 related articles for article (PubMed ID: 20306673)
1. Prevalence and prognostic significance of murine double minute protein-2 overexpression and P53 gene mutations in childhood acute lymphoblastic leukemia.
Hendy OM; Elghannam DM; El-Sharnouby JA; Goda EF; El-Ashry R; Al-Tonbary Y
Egypt J Immunol; 2008; 15(1):93-100. PubMed ID: 20306673
[TBL] [Abstract][Full Text] [Related]
2. Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia.
Hendy OM; Elghannam DM; El-Sharnouby JA; Goda EF; El-Ashry R; Al-Tonbary Y
Hematology; 2009 Dec; 14(6):335-40. PubMed ID: 19941740
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia.
Marks DI; Kurz BW; Link MP; Ng E; Shuster JJ; Lauer SJ; Carroll D; Brodsky I; Haines DS
J Clin Oncol; 1997 Mar; 15(3):1158-62. PubMed ID: 9060559
[TBL] [Abstract][Full Text] [Related]
4. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis.
Marks DI; Kurz BW; Link MP; Ng E; Shuster JJ; Lauer SJ; Brodsky I; Haines DS
Blood; 1996 Feb; 87(3):1155-61. PubMed ID: 8562942
[TBL] [Abstract][Full Text] [Related]
5. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Abshire TC; Homans A; Billett AL; Yeager AM; Findley HW
Leukemia; 2000 Jan; 14(1):61-7. PubMed ID: 10637478
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
Ociepa T; Maloney E; Kamieńska E; Wysocki M; Kurylak A; Matysiak M; Urasiński T; Urasińska E; Domagała W
Pol J Pathol; 2010; 61(4):199-205. PubMed ID: 21290342
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.
Tsai T; Davalath S; Rankin C; Radich JP; Head D; Appelbaum FR; Boldt DH
Leukemia; 1996 Dec; 10(12):1901-10. PubMed ID: 8946929
[TBL] [Abstract][Full Text] [Related]
9. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors.
Gustafsson B; Axelsson B; Gustafsson B; Christensson B; Winiarski J
Pediatr Hematol Oncol; 2001 Dec; 18(8):497-508. PubMed ID: 11764099
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
11. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MDM2 in acute childhood lymphoblastic leukemia.
Gustafsson B; Stål O; Gustafsson B
Pediatr Hematol Oncol; 1998; 15(6):519-26. PubMed ID: 9842645
[TBL] [Abstract][Full Text] [Related]
13. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
15. Expression and significance of P53 protein and MDM-2 protein in human gliomas.
Wang AL; Liu ZX; Li G; Zhang LW
Chin Med J (Engl); 2011 Aug; 124(16):2530-3. PubMed ID: 21933600
[TBL] [Abstract][Full Text] [Related]
16. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Zhou M; Yeager AM; Smith SD; Findley HW
Blood; 1995 Mar; 85(6):1608-14. PubMed ID: 7888679
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.
Wilda M; Bruch J; Harder L; Rawer D; Reiter A; Borkhardt A; Woessmann W
Leukemia; 2004 Mar; 18(3):584-8. PubMed ID: 14712292
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
